MedTrace Logo

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

NCT02589821 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2023-03-30

No results posted yet for this study

Summary

A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced pancreatic neuroendocrine tumors.

Conditions

Interventions

DRUG

Surufatinib

Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle

OTHER

Placebo

Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Sponsors & Collaborators

  • Hutchison Medipharma Limited

    lead INDUSTRY

Principal Investigators

  • Songhua Fan, MD · Hutchison Medi Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-07
Primary Completion
2019-11-11
Completion
2022-07-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02589821 on ClinicalTrials.gov